Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6710735 | 0.87 | SLC6A4 (0.68) | SLC6A4DRD2ADRA1DHRH3SIGMAR1 | |
| SCHEMBL6788939 | 0.85 | DRD2 (0.50) | SLC6A4DRD2ADRA1DHRH3HTR7 | |
| SCHEMBL9032338 | 0.83 | SLC6A4 (0.70) | SLC6A4DRD2ADRA1DHRH3BCHE | |
| SCHEMBL6710692 | 0.82 | DRD2 (0.49) | SLC6A4DRD2ADRA1DHTR7 | |
| SCHEMBL6720905 | 0.82 | SLC6A4 (0.54) | SLC6A4DRD2ADRA1DHRH3SIGMAR1 | |
| SCHEMBL6789060 | 0.78 | SLC6A4 (0.54) | SLC6A4DRD2HRH3HTR7 | |
| SCHEMBL6791223 | 0.78 | SLC6A4 (0.49) | SLC6A4DRD2ADRA1DHRH3HTR7 | |
| SCHEMBL9323878 | 0.77 | SLC6A4 (0.74) | SLC6A4DRD2ADRA1DHRH3 | |
| SCHEMBL6790827 | 0.75 | SLC6A4 (0.48) | SLC6A4DRD2HRH3 | |
| Hydrochloric Acid SCHEMBL6133316 | 0.74 | SLC6A4 (0.59) | SLC6A4DRD2ADRA1DHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1351935-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351936-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055495-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055496-A1 | ARYL PIPERIDINE AND PIPERAZINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC6A4 969/4885DRD2 152/4885ADRA1D 44/4885 |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | SLC6A4 812/4885DRD2 269/4885ADRA1D 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.